Drug intelligence / Profile preview

DA-5219

Development stage: Phase 3
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-5219 is an orally administered small molecule drug candidate under development by Dong-A ST for the treatment of acute or chronic gastritis. It is currently in Phase III clinical trials for this indication. The specific mechanism of action has not been disclosed as of the latest updates. The drug is formulated as a tablet and does not have orphan drug status.

Beyond the preview

Go deeper on DA-5219.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5219.

Explore the full profile